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Abstract: MeCP2 is a fundamental protein associated with several neurological disorders,
including Rett syndrome. It is considered a multifunctional factor with a prominent role
in regulating chromatin structure; however, a full comprehension of the consequences
of its deficiency is still lacking. Here, we characterize a novel mouse model of Mecp2
bearing the human mutation Y120D, which is localized in the methyl-binding domain.
As most models of Mecp2, the Mecp2Y120D mouse develops a severe Rett-like
phenotype. This mutation alters the interaction of the protein with chromatin but
surprisingly it also impairs its association with corepressors independently on the
involved interacting domains. These features, which become overt mainly in the
mature brain, cause a more accessible and transcriptionally active chromatin structure;
conversely, in the Mecp2-null brain we find a less accessible and transcriptionally
inactive chromatin.
By demonstrating that different MECP2 mutations can produce concordant
neurological phenotypes but discordant molecular features, we highlight the
importance of considering personalized approaches for the treatment of Rett
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ABSTRACT 
MeCP2 is a fundamental protein associated with several neurological disorders, including Rett syndrome. 
It is considered a multifunctional factor with a prominent role in regulating chromatin structure; however, 
a full comprehension of the consequences of its deficiency is still lacking. Here, we characterize a novel 
mouse model of Mecp2 bearing the human mutation Y120D, which is localized in the methyl-binding 
domain.  As most models of Mecp2, the Mecp2Y120D mouse develops a severe Rett-like phenotype. This 
mutation alters the interaction of the protein with chromatin but surprisingly it also impairs its association 
with corepressors independently on the involved interacting domains. These features, which become 
overt mainly in the mature brain, cause a more accessible and transcriptionally active chromatin structure; 
conversely, in the Mecp2-null brain we find a less accessible and transcriptionally inactive chromatin. 
By demonstrating that different MECP2 mutations can produce concordant neurological phenotypes but 
discordant molecular features, we highlight the importance of considering personalized approaches for 
the treatment of Rett syndrome. 
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Mutations in the X-linked MECP2 (methyl-CpG-binding protein 2) gene cause a large spectrum of 
neurological disorders. Among these, Rett syndrome (RTT, OMIM #312750) was the first identified and 
remains the most thoroughly characterized MECP2-related disorder [1, 2]. RTT is a pediatric 
neurodevelopmental disease that typically affects girls, as males fail to survive beyond the first few years 
of life. Hallmark of typical RTT is the regression of language and hand use after a period of apparently 
normal development that usually lasts 6-18 months. During and after this regression phase, patients 
develop a host of symptoms that typically include intellectual disability, respiratory abnormalities, hand 
stereotypies, ataxia, absence of speech, autonomic dysfunctions and epilepsy.  
Although a comprehensive understanding of all its functions is still missing, MeCP2 is commonly 
defined as a ubiquitously expressed multifunctional protein mainly working as a transcriptional 
repressor. MeCP2, in fact, consists of two fundamental domains: a methyl-CpG binding domain (MBD) 
mediating its preferential binding to methylated DNA and a transcriptional repression domain (TRD) 
inhibiting gene expression through different mechanisms, including the recruitment of chromatin 
remodeling complexes to methylated DNA [3–6]. Moreover, in mature neurons, where MeCP2 is very 
abundant, the protein acts as an alternative linker histone, organizing a specialized chromatin structure 
that dampens transcriptional noise [7]. 
Even if most cases of RTT are caused by missense and nonsense mutations in MECP2, the first and so 
far most studied Mecp2 model has been the full knockout mouse, generated and described in refs. [8, 9]. 
However, to mimic RTT more closely, few more animal models carrying human pathogenic mutations 
have been generated [10, 11]. 
Typically, Mecp2 mouse models recapitulate many RTT features. In particular, the hemizygous males 
appear grossly normal in the perinatal period but later they develop a progressive neurological phenotype 
whose onset and severity depend on the specific genetic mutation. These mice manifest locomotor 
deficits, hind limb clasping, hypotonia, reduced spontaneous movements, tremors, breathing defects and 
seizures [10]. While the complete absence of Mecp2 results in a premature death, generally occurring 
between 56 to 80 days of life [8, 9], the lifespan of knockin mice can vary from 95-110 days to more 
than 300, according to the severity of the mutation [12]. 
Interestingly, several lines of evidence suggest that in null animals Mecp2 functions might be replaced 
by one or more other proteins, which therefore mask the consequences of its lack [7]. This suggests the 
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importance of producing knockin models, that by ensuring the presence of the mutated protein, might 
provide better insights into MeCP2 functions [5, 10, 12–14]. For example, the Mecp2R306C model was 
pivotal in revealing the recruitment of the NCoR/SMRT corepressor on DNA as a core MeCP2 function 
[5]. Similarly, Mecp2T158M and Mecp2R133C mutations in mice were instrumental to determine the role of 
the MBD on protein stability and chromatin binding [12]. 
We have recently highlighted the relevance of Tyr-120 (Y120) residue for MeCP2 structure and function 
[15]. Its involvement in RTT was suggested by the identification of a patient carrying the pathogenic 
substitution of Y120 with aspartic acid (Y120D) [16]. The residue Y120 is located in the MBD of MeCP2 
and it is highly conserved in mammals. In accordance with its location, we proved that the substitution 
of residue Y120 with a D impairs the ability of the MBD to interact with DNA [15]. Accordingly, 
previous studies demonstrated that an exogenously expressed MeCP2-Y120D derivative features a 
decreased affinity for heterochromatin [17, 18]. 
Based on these evidences and driven by the idea that specific mutations produce molecular consequences 
that might differ from the lack of Mecp2, we generated a novel mouse model carrying the human 
pathogenic mutation Y120D. We demonstrate that Mecp2Y120D mice show a harsh behavioral phenotype 
that is only slightly less severe than Mecp2-null mice. At the molecular level, the Y120D mutation 
impairs the ability of Mecp2 to acquire a tight binding to chromatin mainly in mature neurons and to 
recruit corepressors on heterochromatin. As a consequence, compared to the Mecp2-null model, the 
Y120D adult brain is characterized by a globally more open chromatin structure. Our data suggest that, 
in spite of overlapping RTT-like symptoms, different mouse models of Mecp2 might display largely 
different molecular phenotypes, a novel perspective for the field of Mecp2 studies. Furthermore, while 
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our results reinforce the idea that Mecp2 functions change with brain maturation [7, 19], they challenge 
the general perception of the impact of Mecp2 mutations on neuronal chromatin architecture. 
 
MATERIALS AND METHODS 
Plasmids 
Human eGFP-MeCP2-WT and its mutant derivatives eGFP-MeCP2-Y120D and -Y120F were obtained 
and described in [20]. The TBL1-mCherry construct [5] was kindly provided by Dr. Adrian Bird 
(Wellcome Trust Centre for Cell Biology, University of Edinburgh, United Kingdom). 
Animal husbandry 
Both mouse lines were housed in the animal facility of the San Raffaele Scientific Institute of Milan. 
Generation of the knockin (KI) mouse line is described in Supplementary Materials and Fig.S1. 
Mecp2Y120D/y males, heterozygous females and wild-type (WT) controls were obtained by crossing 
heterozygous females with WT males of either C57BL/6J or CD1 background purchased from Charles 
River. Genotyping was performed through PCR on genomic DNA purified from tail biopsies, using the 
following   primers:   common   forward   5’–CAGGGCCTCAGAGACAAGC–3’;;   common   reverse   5’–
GCAGATCGGCCAGACTTCC–3’;;   reverse   for   the   KI   allele   5’–
GGGTTAATTGATATCCAATTGGGATCC–3’.  A  300  bp  fragment  is  common  for  WT  and  knockin  
animals, while a 550 bp fragment is specific for the mutated one. When needed (e.g. embryos for primary 
cell cultures or small pups), the animal sex was determined by using primers recognizing Jarid1 (forward 
5’–CCAGGATCTGACGACTTTCTACC–3’,   reverse   5’–TTCTCCGCAATGGGTCTGATT–3’),  
which produce a PCR fragment only in males.  
Mating and genotyping of the CD1 Mecp2Bird mouse line are described in [21]. 
All procedures were performed in accordance with the European Community Council Directive 
2010/63/UE for care and use of experimental animals; all the protocols were approved by the Italian 
Minister for Scientific Research and by the San Raffaele Scientific Institutional Animal Care and Use 
Committee in accordance with the Italian law. 
Phenotypic evaluation 
C57BL/6J or CD1 knockin mice and WT littermates were weekly tested for the presence or absence of 
RTT-like symptoms with a previously described scoring system [22]. During each session, mice were 
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weighed and scored for their general condition, mobility, hind limb clasping and (only for CD1) tremor. 
Of note, the intermediate values of 0.5 and 1.5 were added to the canonical scores between 0 and 2 to 
provide a more detailed description of the phenotypic variability (for details see Supplementary 
Materials). All animals scoring 2 for general condition or tremor or rapidly losing weight were euthanized 
for ethical reasons. At the experimental endpoint, animals were euthanized through cervical dislocation 
after deep anesthesia with Avertin (Sigma-Aldrich, St Louis, MO, USA). At the time of death, brains 
were quickly removed, weighed and cortices dissected on ice. Day of euthanasia was considered as day 
of death without distinguishing it from natural death.  
Behavioral assessment 
Animals were maintained on an inverted 12 h light/darkness cycle at 22-24°C.  
Rotarod. Rotarod apparatus is composed by a horizontal rotating rod (diameter 3 cm) on which mice, 
separated by large disks, have to keep their balance. The test was carried out in 2 days. Each day, 5 trials 
of 5 min, separated by intervals of 30 min, were presented to the mice. On day 1, mice were placed on 
the apparatus with the rod rotating at 4 rpm (rotations/minute) for 1 min, then the rotation speed was 
increased every 30 sec by 4 rpm. On day 2, mice were tested at a constant rotation speed corresponding 
to the average of the maximum speeds reached from all mice during day 1. A trial ended when the mouse 
fell down or after 5 min. The latency to fall down from the rod was taken as the dependent variable for 
every trial and was normalized for the mouse weight. 
Grip. Grip test was performed with a horizontal metal bar (grip) strength dynamometer that mice grasp 
with the forelimb while suspended by their tail. Animals were gently pulled backward until they released 
the grip. The dependent variable was the maximal value obtained on a total of six trials.  
Catwalk. Gait analysis was performed by using CatWalk XT System (Noldus Information Technology, 
Wageningen, the Netherlands, http://www.noldus.com). Mice were allowed to freely ambulate along an 
illuminated glass plate within a confined corridor (50x8 cm) in a darkened room; footprints were 
recorded with a high-speed camera and subsequently analyzed with CatWalk XT 10.0 software (Noldus). 
Three trials/animal were analyzed and averaged to obtain stride length and base of support for front and 
hind right and left paws.  
Spontaneous alternation. The test was performed in a dim illuminated room and mice were habituated 
to the environment for 1 hour before the test. The apparatus consisted in a cross maze with a central hub 
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where the mouse was released and left free to explore for 10 min. Number and sequence of entries in 
each arm were recorded throughout the test. An alternation was considered correct when no more than 
one repetition over five entries was made. 
Trace Fear Conditioning. Auditory trace and delay fear conditioning were performed by placing the mice 
in an opaque conditioning chamber (L x W x H: 25x17x23 cm; UgoBasile Instrument [Gemonio, Italy]) 
with a grid floor through which scrambled foot shocks could be delivered as unconditioned stimuli (US; 
0.26 mA average intensity). The chamber was placed into a dimly lit (<5 lx) sound attenuating box 
(background noise level 55dB), and a speaker on top of the chamber allowed to deliver sounds as 
conditioning stimuli (CS; 2000Hz).  
All mice were pre-exposed to the test chamber for 10 min on the day before conditioning. Conditioning 
consisted in 1 min of baseline period (no stimulus) followed by 5 trials separated by 1 min of inter-trial 
intervals (ITI). In the trace fear conditioning, every trial is composed by the presentation of the CS (15 
sec) followed, 15 sec later (trace), by the presentation of the shock for 2 sec. The freezing behavior was 
measured during the presentation of the CS. Twenty-four hours after fear conditioning, mice were placed 
again in the conditioning box, measuring their freezing behavior in the context test and tone test. Context 
testing consisted of 2 min  without  CS  (“contextual  freezing”);;  tone  testing  consisted  of  1 min without 
CS followed by 1 min with the CS turned on in a new environment.  
Data analysis. During Dark & Light, Emergence and Novelty tests, animals were video-tracked using 
the EthoVision 2.3 system (Noldus Information Technology) with an image frequency of 4.2/sec. Raw 
data were transferred to Wintrack 2.4 for off-line analyses (http://www.dpwolfer.ch/wintrack). During 
Fear conditioning test, animals were continuously video-tracked using the ANY-maze system (Anymaze, 
Stoelting Co, Wood Dale, IL, USA, www.anymaze.com). The frequency of freezing (absence of 
movements except respiration) was continuously recorded. Statistical computations were done using 
Statview 5.0 (SAS Institute, Cary, NC, USA). Analysis of variance (ANOVA), alpha value 5%, with 
factorial measures was used to test the statistical significance between genotypes effect.  
Primary cell cultures 
WT and Mecp2Y120D/y neurons were prepared from E15.5 or E17.5 cortices isolated from pregnant 
heterozygous females. Dissected tissues were washed in HBSS (Life-Technologies, Carlsbad, CA, USA), 
digested with 0.25% Trypsin-EDTA (Invitrogen, Carlsbad, CA, USA) and mechanically dissociated in 
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dissecting medium (DMEM [Sigma-Aldrich], 10% Horse serum [Euroclone, Pero, MI, Italy], 1% 
glutamine [Sigma-Aldrich]). Cells were resuspended in neuronal culture medium (Neurobasal [Life 
Technologies], 2% B-27 [Life Technologies], 1% glutamine) and plated on 0.1 mg/ml poly-L-lysine 
(Sigma-Aldrich) both on 6-multiwell plates at a density of 200000 cells/well and on 24-multiwell plates 
(containing glass coverslips) at a density of 20000 cells/well. 
Mecp2-null mouse embryonic fibroblasts (MEF) were prepared from Mecp2-/y CD1 E14.5 embryos as 
previously described [20]. For DNA transfection, MEFs were plated on 12-multiwell plates on glass 
coverslips and transfected with lipofectamine 3000 (Invitrogen) as instructed by the manufacturer. Cells 
were analyzed 24 hours after transfection.  
Western Blot 
Whole brains and cortices harvested from Mecp2+/y and Mecp2Y120D/y mice were mechanically 
homogenized with a Potter-ELV glass grinder in lysis buffer (50 mM Tris-HCl pH 7.4, 500 mM NaCl, 
1% Triton X-100, 2 mM EDTA, 1 mM DTT, 1X PhosSTOP [Roche, Basel, Switzerland], 1X complete 
EDTA-free protease inhibitor cocktail [Roche]). Lysates were incubated 30 min on ice and sonicated 
(Amplitude=100%, three pulses for a total of 13 min). After centrifugation at 13000 rpm at 4°C for 15 
min, supernatant was collected. Neurons from 6-multiwell plates were directly lysed in Laemmli buffer 
6X and sonicated (A=100%, for 13 min). Proteins were electrophoretically separated on SDS-
polyacrylamide gel and blotted on a nitrocellulose membrane using the Trans-Blot Turbo Transfer 
System from Bio-Rad (Hercules, CA, USA). Membranes were incubated 30 min in blocking solution 
(Tris-buffered saline containing 5% nonfat milk and 0.1% Tween-20, pH 7.4) and then incubated with 
the primary antibody diluted in blocking solution overnight at 4°C. The following primary antibodies 
were  used:  rabbit  α-MeCP2 (1:1000; Sigma-Aldrich),  mouse  α-TuJ1 (1:10000; Sigma-Aldrich), rabbit 
α-rpS6  (5G10,  1:1000;;  Cell  Signaling  Technology,  Danvers,  MA,  USA),  rabbit  α-P-rpS6 (Ser240/244, 
1:1000;;  Cell  Signaling  Technology),  rabbit  α-P-S164 (1:1000; Covance, Princeton, NJ, USA), rabbit  α-
H1 (1:1000; GeneTex, Irvine, CA, USA). Secondary antibodies were either fluorescent (1:2000 
AlexaFluor 488; Life Technologies) or HRP-conjugated (1:10000; Cell Signaling Technology). Signals 
were visualized and acquired using the fluorescence laser scanner Typhoon FLA 9000 or using the 
Chemiluminescence detection systems UVITEC ChemiDoc (Alliance 9.7, UVITEC Cambridge) or 
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ChemiDoc Touch Imaging System (Biorad). Quantitative analyses were performed using either ImageJ 
software or ImageLab software from Bio-Rad. 
Immunofluorescence and histology 
Cells cultured on glass coverslips were washed with PBS and fixed in 4% paraformaldehyde (PFA) for 
20 min at room temperature (RT). Neurons were then permeabilized in 0.1% Tween-20 for 10 min at RT 
and blocked for 1 hour at RT (blocking solution: 10% horse serum [Euroclone], 0.1% Triton X-100 in 
PBS),  followed  by  an  overnight  incubation  at  4°C  with  the  rabbit  α-MeCP2 primary antibody (1:100; 
Sigma-Aldrich) diluted in blocking solution. Cells were incubated with fluorescent secondary antibody 
(AlexaFluor  488  α-rabbit, 1:500 in blocking solution) for 1 hour at RT. Finally, DNA was counterstained 
with DAPI (1:1000 in PBS; Invitrogen) for 10 min at RT and coverslips were mounted with Prolong 
Gold reagent (Invitrogen).  
Transfected MEFs were stained with DAPI (10 min at RT) after fixation. Images were acquired using 
Nikon microscope, objectives and software. 
Mice were transcardially perfused with 4% PFA. Brains were harvested, cryoprotected in sucrose 30%, 
embedded in Tissue-Tek O.C.T. Compound (Sakura Finetek, Alphen aan den Rijn, The Netherlands) and 
cut in 12 µm sections. Sections were washed thoroughly in PBS, antigen retrieved in 10 mM sodium 
citrate, washed in 0.01% Tween-20 and incubated in 0.1 M glycine. Tissues were blocked in blocking 
solution  and  incubated  with  antibodies  as  above  (primary  antibody:  α-ATRX H-300 1:100; Santa Cruz 
Biotechnology,   Dallas,   TX,   USA.   Secondary   antibody:   AlexaFluor   568   α-rabbit, 1:500). After 
counterstaining with DAPI, sections were mounted with Fluoromount-G (eBioscience, San Diego, CA, 
USA). Images were acquired using a Leica SP5 confocal microscope.   
RNA Pol II-S5P staining was performed on nuclei isolated from Mecp2+/y, Mecp2Y120D/y and Mecp2-/y 
cortices at P40 (as described beneath in the Chromatin accessibility assay section). In detail, nuclei were 
permeabilized in PBST (0.01% Triton X-100 in PBS), fixed in 4% PFA and spotted on slides prior 
staining. Nuclei were then blocked for 1 hour at room temperature (RT) and incubated overnight at 4°C 
with α-RNA Polymerase II-S5P (1:100, Abcam, ab5131). After washing in PBS, nuclei were incubated 
with  AlexaFluor  488  α-rabbit (1:500; Life Technologies) for 2 hours at RT, counterstained with DAPI 
for 10 min at RT and finally mounted with Fluoromount-G (eBioscience). All images were acquired 
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using a Leica SP5 confocal microscope and the RNA Polymerase II-SP5 activity was evaluated by 
measuring the intensity of the nuclear α-RNA Polymerase II-S5P signal using ImageJ Software.  
Salt extraction assay 
Mecp2 chromatin affinity was assessed in brain tissues by performing salt extraction assays as described 
in refs. [3, 19]. 
RNA purification, cDNA synthesis and qPCR 
Total RNA was extracted from Mecp2+/y and Mecp2Y120D/y cortices using the RNeasy Mini Kit (QIAGEN, 
Hilden, Germany) following the manufacturer’s  instructions. RNA quality was assessed on 1% agarose 
gel. Total RNA was retro-transcribed using the RT2 First Strand Kit (QIAGEN). qPCRs were performed 
using SYBR Select Master Mix (Applied Biosystems, Foster City, CA, USA) and the following primers:  
Mecp2:  
- Forward:  5’  AAACCACCTAAGAAGCCCAAATC  3’ 
- Reverse:  5’  TTGACAACAAGTTTCCCAGGG  3’ 
18S: 
- Forward:  5’ GTAACCCGTTGAACCCCATT  3’   
- Reverse:  5’  CCATCCAATCGGTAGTAGCG  3’ 
 All samples were evaluated in triplicate and 18S was used as normalizer.      
Calcium imaging in cultured neurons  
Cortical neurons at days in vitro (DIV) 4 or 13 were loaded with 5 mM of the ratiometric Ca2+ dye Fura-
2 pentacetoxymethylester (Sigma-Aldrich) dissolved directly in neuronal medium solution for 35-40 min 
at 37°C, washed and transferred to the recording chamber of an inverted microscope (Axiovert 100; 
Zeiss, Oberkochen, Germany) equipped with a calcium imaging unit [23]. Fluorescence images were 
obtained by alternatively illuminating cells at 345 nm and 380 nm wavelength and images (345 nm or 
380 nm) were acquired at 1 Hz frequency. After baseline acquisition, neurons were stimulated with 100 
M NMDA (Tocris) followed by 50 mM KCl. Temporal Ca2+ intensity profiles (expressed as F340/380 
fluorescence ratio) were calculated in discrete areas of interest from image sequences. Changes over 
baseline in the F340/380   fluorescence   ratio  higher   than  “100”  were   considered   “calcium  peak”.  To  
induce an appropriate NMDA stimulation, experiments were conducted in Mg2+-free Krebs-Ringer 
solution (KRH, in order to remove the Mg2+ block from the receptor) with tetrodotoxin 1 mM (TTX), 
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while the KCl-induced depolarization has been reached by using normal KRH with 1 M TTX. Calcium 
transients were analyzed in about 150-200 cells per experimental group (as specified in legends). Nine 
glasses per group (1 field/glass) were analyzed at each developmental point. 
Chromatin accessibility assay 
To maintain nuclei intact, Mecp2+/y, Mecp2Y120D/y and Mecp2-/y brains were mechanically homogenized 
on ice with Potter-ELV glass grinder in buffer A (0.25 M sucrose, 60 mM KCl, 15 mM NaCl, 10 mM 
MES pH 6.5, 5 mM MgCl2, 1 mM CaCl2, 0.5% Triton X-100, 1X PhosSTOP [Roche], 1X complete 
EDTA-free protease inhibitor cocktail [Roche]). Samples were incubated on ice for 10 min and 
centrifuged at 7000 rpm at 4°C for 10 min. Supernatants were discarded and nuclei were washed with 
buffer A. Nuclear pellets were resuspended in the digestion buffer B (50 mM NaCl, 10 mM Pipes pH 
6.8, 5 mM MgCl2, 1 mM CaCl2, 1X PhosSTOP, 1X complete EDTA-free protease inhibitor cocktail). 
Fifty µl of each sample were collected, supplemented with 3 µl of 0.5 M EDTA and conserved as the 
undigested fractions. The remaining volume was pre-warmed at 37°C and supplemented with 2.5 Units 
of MNase (Worthington Biochemical Corporation, Lakewood, NJ, USA) per 10 million of nuclei. 
Digested fractions were collected at the indicated time points. MNase digestion was stopped by adding 
3 µl of 0.5 M EDTA to each fraction. DNA was phenol/chloroform extracted and quantified. For each 
fraction, 10 µg of DNA were loaded on a 2% EtBr agarose gel, which was run for approximately 5 hours. 
For each time point, ImageJ was used to obtain a densitometry plot and the amount of mononuclesomal 
DNA normalized on total DNA was plotted to highlight differences in the digestion rate between 
experimental groups. 
DAPI staining of MNase-treated nuclei 
Fresh isolated nuclei were obtained as above. Samples were resuspended in 300 µl of buffer B and 2.5 
Units/50 µl of MNase were added. Reactions were performed at 37°C and stopped at 0, 5, and 10 min 
by adding 3 l of 0.5 M EDTA. Nuclei were then fixed in 4% PFA for 5 min, spotted on a glass coverslip 
and stained with DAPI for 10 min at RT. Nuclei were mounted with Fluoromount-G and imaged using a 
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Leica SP5 confocal microscope. DAPI intensity and heterochromatin area were calculated by using 
ImageJ software. 
5-hmC DNA ELISA assay 
Brain cortices were harvested from Mecp2+/y, Mecp2Y120D/y and Mecp2-/y P40 mice. Genomic DNA was 
extracted from ≤25  mg  of  frozen  brain cortices by using the Quick-DNA™  Miniprep  Plus  Kit  (Zymo  
Research,  Irvine,  CA,  USA)  according  to  the  manufacturer’s  instructions, with the exception that tissues 
were digested overnight with proteinase K. The percentage of 5-hmC in 100 ng of single-stranded DNA 
was quantified with  the  Quest  5hmC™  DNA  ELISA  Kit  (Zymo  Research),  following  the  manufacturer’s  
instructions. HRP color was allowed to develop for 30 min before reading plates at 415 nm with the 
Microplate Reader Model 680 (Bio-Rad). 
RESULTS 
Mecp2Y120D knockin mice manifest a severe RTT-like phenotype and short lifespan 
The mouse line carrying the human Y120D mutation was generated on a C57BL/6J background 
(Mecp2Y120D mice; Fig.1a; see Supplementary Materials and Fig.S1 for a detailed description of the 
procedures). Sequencing of hemizygous mutant mice, screened by PCR, proved the presence of the 
expected mutation (Fig.1b). 
While the colony was maintained on a C57BL/6J background, the mutant allele was also transferred on 
a CD1 (ICR) genetic background; the advantages of the CD1 background in Mecp2 studies are described 
in ref. [21]. Colonies were maintained by crossing heterozygous females to wild-type (WT) males, since 
hemizygous males were unable to induce pregnancy. To be noticed, the generated mutation does not 
affect Mecp2 mRNA levels (Fig.1c). 
The severity of the Mecp2-Y120D mutation was evaluated using a well-established panel of parameters 
which include lifespan and phenotypic score [22]. As depicted in Fig.1d, hemizygous Mecp2Y120D males 
died prematurely (average lifespan of 97 and 121 days in the C57BL/6J and CD1 background, 
respectively). After weaning, mutated males became progressively symptomatic, as indicated by the 
increased phenotypic score (Fig.1e; Supplementary Materials and Fig.S2). On the other hand, 
heterozygous CD1 Mecp2Y120D females started showing typical RTT-like features only at 9 weeks of age 
(Fig.1f; Supplementary Materials and Fig.S2) and they did not manifest any apparent reduced longevity 
in the first year of life. C57BL/6J heterozygous females were not analyzed in this study because in a time 
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frame of over two years we did not succeed in generating a sufficient number of animals. In both sexes, 
similarly to null animals [21], tremor was the first symptom to appear along with worsening of the general 
conditions, while hind limb clasping and altered mobility appeared later and were characterized by higher 
variability (Supplementary Materials and Fig.S2). Body weight of Mecp2 animal models generally 
depends on mutation, sex and genetic background [21]; indeed, C57BL/6J Mecp2-null mice are 
notoriously underweight compared to WT, while the corresponding females are generally heavier. 
Compared to WT, Mecp2-null male animals on a CD1 background show no difference in body weight 
both at early and late postnatal time points. However, CD1 heterozygous females have a strong tendency 
towards obesity [21]. Our data show that while C57BL/6J Mecp2Y120D males were always lighter than 
WT littermates, CD1 mutated males showed a tendency to be lighter soon after birth, while becoming 
generally overweight in adulthood (Fig.1g). Conversely, the body weight of CD1 Mecp2Y120D 
heterozygous females was indistinguishable from WT littermates at early postnatal days, but it 
progressively increased with aging, leading to obesity (Fig.1h). 
An early diagnostic criterion for Rett syndrome is deceleration of head growth, which often leads to 
microcephaly in infancy. Similarly, most of the Mecp2 animals generated so far (with the exception of 
the Mecp2308X mice [24]) are characterized by decreased brain size and weight. We weighted brains of 
pre- (P18) and symptomatic (P40 and P>130) CD1 Mecp2Y120D males. Compared to WT, CD1 mutant 
brains exhibited an overall weight reduction of 12%, 13.5% and 17.5% at P18, P40 and P>130, 
respectively; brains from symptomatic C57BL/6J Mecp2Y120D males (P>80) had a 15.7% of weight 
reduction compared to WT brains (Fig.1i). 
The presence of RTT-like phenotypes was also analyzed through a battery of behavioral tests on CD1 
Mecp2Y120D male mice and littermate controls. Results are summarized in Fig.2 and Table S1. Rotarod 
(Fig.2a), CatWalk (Fig.2b, c) and grip (Fig.2d) tests highlighted significant deficits in motor 
coordination, gait and anterior paws strength in juvenile (P30) and/or adult (P60) Mecp2Y120D mice. 
We next examined learning ability of P30 and P60 Mecp2Y120D mice by performing the spontaneous 
alternation test. Working memory impairment was evident at P30, when knockin mice showed more than 
30% reduction of correct responses with respect to controls, with no difference in the total number of 
visits (Fig.2e). P60 data have been omitted since the considerable decrease in spontaneous locomotor 
activity confounded the interpretation of results. We also found a deficit in associative memory through 
contextual and cued fear-conditioning tests (Fig.2f). Juvenile and adult knockin mice showed significant 
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reduced freezing during the cue exposure 24 h after training, suggesting a specific impairment in the 
conditioned stimulus memory. By performing most of these tests also with CD1 Mecp2 null mice, we 
revealed that both Mecp2 lines manifest very similar behavioral performances (Fig.S3). 
Anxiety-like and explorative behaviors were also assayed through different approaches (Supplementary 
Materials and Table S1) but no significant defect was observed. Notably, while anxiety is a common trait 
of RTT patients, in Mecp2 animal models this feature depends on the specific genetic mutation [25]. 
We completed the preliminary assessment of phenotypes typically evaluated in Mecp2 animal models by 
testing whether knockin neurons exhibit functional defects similar to the Mecp2-null cells. We recently 
demonstrated that both in vivo and in vitro Mecp2-null neurons are characterized by a delayed maturation 
and impaired intrinsic responsiveness to external stimuli [26]. Thus, we cultured E15.5 Mecp2Y120D 
cortical neurons and probed neuronal responsiveness; the analyses were performed on immature (DIV4) 
or more mature (DIV13) neurons (Fig.2g). Calcium imaging analyses showed that the amplitude of KCl-
induced calcium transients is reduced in mutated neurons both at DIV4 and 13, confirming an impairment 
in the expression/sensitivity of voltage-operated calcium channels (VOCCs) and consequently a 
defective neuronal responsiveness to depolarization. Calcium imaging was also used to obtain 
information on the expression of functional NMDA receptors (Fig.2h). Whereas immature Mecp2Y120D 
neurons showed a significant reduction in NMDA-induced calcium peaks, mature neurons exhibited 
normal calcium transients associated with NMDA stimulation in spite of lower response to KCl. These 
data confirm that Mecp2 mutations affect neuronal responsiveness; further, they suggest that Mecp2-
related phenotypes change along neuronal maturation. 
Y120D mutation affects Mecp2 abundance and chromatin binding mainly in mature neurons 
To gain insights into the molecular mechanisms responsible for the phenotypes affecting Mecp2Y120D 
mice, we assessed Mecp2 levels and other molecular markers typically associated with Mecp2 functions. 
The results show that, while Mecp2-Y120D levels were normal in immature brains (E16, P6), they were 
significantly lower at P18 (-56±4%, ***P<0.001, Student's t test; Fig.3a) and P40 (-62±4%, 
****P<0.0001, Student's t test; Fig.3a); a similar pattern was confirmed in in vitro cultured neurons 
(DIV7: -29.7±12.3%; DIV14: -35.7±13.3%, *P<0.05, Student's t test; Fig.3b). 
In line with the Mecp2-null model, the mature knockin brain (P40) exhibited a reduction in rpS6 
phosphorylation (-43±4%, *P<0.05, Student's t test; Fig.3c, upper panel), a hallmark of RTT progression 
[27, 28]. Recently, we have demonstrated that phosphorylation of MeCP2 on Ser164 (S164), which is 
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downregulated during neuronal maturation, globally diminishes MeCP2 binding to chromatin [19]. We 
thus assessed the levels of this phosphorylation in Mecp2Y120D/y adult mice, finding that it is significantly 
increased compared to WT (+193±30%, ***P<0.001, Student's t test; Fig.3c, lower panel). 
Since a 50% reduction of protein levels in mice cannot explain the severity of the observed phenotype 
[29], we proceeded analyzing the consequences of Y120D mutation on Mecp2 activity. Previous studies 
demonstrated that the MeCP2-Y120D mutant exogenously expressed in non-neuronal cells shows a 
reduced accumulation on heterochromatic foci [17, 18]. To confirm these results in cells expressing 
physiological levels of Mecp2, we compared the sub-nuclear localization of the WT and mutated proteins 
in cultured cortical neurons (Fig.3d). As expected, while the WT protein showed a clear accumulation 
on highly methylated heterochromatic foci starting from DIV7, Mecp2-Y120D remained mainly diffused 
in the nucleus along all stages of neuronal maturation, forming only few dots that do not overlap with 
DAPI-positive foci. 
Our data thus suggest that the pathogenic mutation might directly and/or indirectly (through S164 
phosphorylation; [19]) impairs Mecp2 affinity to chromatin, with the magnitude of the effect depending 
on brain maturation. Thus, through salt extraction experiments, we compared the affinity for chromatin 
of the WT and mutated protein in immature (P6) and mature (P40) mouse brains (Fig.3e-g). As reported 
[19], in mature brain WT Mecp2 is more tightly associated with chromatin compared to the immature 
brain. On the contrary, at P40 most of the mutant protein was extracted at 300 mM NaCl, therefore failing 
to acquire a tighter association with chromatin (Fig.3f). To confirm this result with a complementary 
assay, an equal amount of brain nuclei isolated from WT and Mecp2Y120D animals (P40) were incubated 
in buffers with increasing ionic strength and the amount of extracted Mecp2 analyzed by western blot 
(Fig.3g). As already demonstrated [3], WT Mecp2 was increasingly extracted at higher salt 
concentrations; indeed, the highest signal was observed at 1M NaCl, while almost no Mecp2 was 
detectable at 200 mM NaCl. On the contrary, most of Mecp2-Y120D was extracted with a much lower 
concentration of NaCl (300-400 mM) with no further increase at 1 M NaCl. Notably, the overall amount 
of the mutant protein was generally decreased in accordance with the protein levels depicted in Fig.3a. 
Although the affinity for chromatin of WT and mutated Mecp2 diverged more clearly in mature brain, 
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quantification of three independent experiments revealed that at P6 Mecp2-Y120D is already less tightly 
bound to chromatin (Fig.3e). 
Together, these data suggest that the Y120D mutation impairs both Mecp2 binding to chromatin and 
protein levels and that these phenotypes become progressively more evident when the WT MeCP2 
acquires mature structural functions [7,19]  
Mecp2Y120D and Mecp2-null brains exhibit different chromatin compaction 
Mecp2 is known to interact with different chromatin remodeling complexes and it is considered to play 
a major role in neuronal chromatin architecture [4, 30]. We thus addressed whether Mecp2-Y120D 
maintains its ability to interact with relevant corepressors, such as NCoR and ATRX and whether this 
mutation affects chromatin compaction. 
Mecp2-null MEFs were cotransfected with eGFP or eGFP-MeCP2 derivatives and TBL1-mCherry, and 
the ability of MeCP2 isoforms to recruit TBL1, part of the NCoR complex, on heterochromatin foci was 
assessed. In accordance with [5, 31], we demonstrated that no cell transfected with eGFP showed co-
localization of TBL1-mCherry with heterochromatic foci (Fig.4a), whereas TBL1 was efficiently 
recruited on the DAPI-positive heterochromatic foci in 58% of cells expressing eGFP-MeCP2-WT and 
in 45% of cells expressing eGFP-MeCP2-Y120F. Importantly, only in 19% of cells expressing MeCP2-
Y120D, TBL1-mCherry colocalized with the heterochromatic foci, suggesting that the interaction 
between Mecp2 and NCoR is significantly affected by the Y120D mutation. Of relevance, the presence 
of smaller and less bright green foci in cells that exogenously express eGFP-MeCP2-Y120D compared 
to cells transfected with eGFP-MeCP2-WT and eGFP-MeCP2-Y120F confirmed the impaired chromatin 
binding ability of the Y120D mutant. 
Considering that the localization of the chromatin remodeling protein ATRX on pericentric 
heterochromatin of mouse neurons depends on its interaction with the MBD of Mecp2 [3, 6], we 
proceeded investigating and revealing a drastic change in ATRX localization in the Mecp2Y120D brain 
with respect to controls (Fig.4b). Together these data confirm that the missense mutation Y120D alters 
the ability of MeCP2 to interact with and/or properly recruit on chromatin its corepressors, therefore 
affecting their sub-nuclear distribution. Given that such corepressors concur to chromatin landscaping, a 
time course of micrococcal nuclease (MNase) digestion of P6 and P40 brain nuclei was performed to 
analyze chromatin accessibility (Fig.5a and Fig.S4). Interestingly, while we were unable to detect any 
overt phenotype in the immature brain (Fig.S4), the MNase digestion pattern at P40 of the Mecp2Y120D/y 
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sample showed a slightly faster accumulation of fragments corresponding to mononucleosomal DNA 
normalized on total DNA (Fig.5a). Quantification of three different experiments demonstrated a 
consistent  trend  that  however  did  not  reach  the  statistical  significance  (Fig.5b’).  By  digesting  WT  and  
Mecp2-null chromatin, the mutant sample appeared mildly less accessible; this tendency was confirmed 
by quantifying three independent experiments (Fig.5b”).   Since   these   results   might   suggest that the 
complete absence of Mecp2 leads to compensatory mechanisms that differ from those generated by the 
presence of the mutated Mecp2, we corroborated these data with a complementary approach. Neuronal 
nuclei were thus purified from Mecp2Y120D/y or Mecp2-null adult (P40) cortices and the corresponding 
WT control tissues, and heterochromatic and euchromatic accessibility was assessed by staining purified 
nuclei with DAPI at different time points of MNase digestion. By measuring both the stained area in 
heterochromatic foci  (Fig.5c’, left panel) and the average DAPI intensity (Fig.5c’’, left panel) in Y120D 
samples, we revealed that euchromatic and heterochromatic DNA is more rapidly digested in mutant 
nuclei, therefore suggesting a globally more accessible chromatin structure. Conversely, MNase 
treatment of Mecp2-null nuclei demonstrated that their heterochromatic DNA, but not bulk chromatin, is 
less digested than the control (Fig.5c’,  c’’, right panels). To verify whether this change in chromatin 
accessibility results in any functional alteration, transcriptional activity within single cortical nuclei was 
investigated by measuring the levels of phosphorylated RNA polymerase II (Pol II–S5P) in Mecp2Y120D/y 
or null P40 nuclei and their corresponding WT controls (Fig.5d; [32–35]). Signal specificity was 
confirmed by the lack of co-localization between DAPI foci (transcriptionally silent heterochromatin) 
and Pol II-S5P signal (transcriptionally active chromatin, Fig.5d). Importantly, a strong and significant 
increase of Pol II-S5P in Mecp2Y120D/y nuclei was observed (+53.4±1.3%, ****P<0.0001, Student's t test; 
Fig.5d’),  while  the  null  nuclei  showed  a  slight but significant reduction with respect to their controls (-
22.9±0.9 %, ****P<0.0001, Student's t test; Fig.5d’’). 
Eventually, we reinforced these data analyzing whether WT, Mecp2-null and Mecp2Y120D/y mature brain 
cortices (P40) differ in their 5-hydromethylcytosine (5-hmC) content. In fact, a direct relationship 
between genome accessibility, transcriptional activity and 5-hmC levels has recently been proposed [36, 
37]. In particular, methylated CG dinucleotides contained in highly compact chromatin are less 
frequently converted to 5-hmC, probably because of lower accessibility of Tet hydroxylases [36]. Fig.5e 
demonstrates that while Mecp2Y120D/y cortices manifest a tendency to an increase in 5-hmC levels, Mecp2-
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null adult brains display a small but significant decrement., as already reported for Mecp2 deficient 
granule cells [38].  
Overall these data support our hypothesis that the presence of Mecp2-Y120D diversely affects the 
general features of brain chromatin compared to the total absence of Mecp2. 
DISCUSSION 
The generation of several mouse models carrying different Mecp2 alterations proved instrumental to 
investigate MeCP2 functions and its involvement in Rett syndrome and MECP2 related disorders [10, 
13]. Mecp2-null animals [8, 9] were the first model generated and still represent the mostly used one. 
However, it has recently become evident that when Mecp2 is absent, its functions are replaced by 
compensatory mechanisms that might mask and confound the consequences of its loss [7]. These results 
highlighted the importance of producing other models with less severe genetic lesions, possibly 
mimicking human mutations [5, 10, 12–14]. Our manuscript describes the generation and the behavioral 
and molecular characterization of a novel knockin mouse model of Rett syndrome carrying the human 
missense mutation MECP2-Y120D, resulting in the substitution of tyrosine 120 (Y) with an aspartic acid 
(D) [16]. Although the Y120 residue of MeCP2 has been linked to RTT only once so far, its involvement 
in MeCP2 affinity for heterochromatin has already been proved [17, 18]. Through molecular dynamics 
simulations, we have recently demonstrated that the Y120D mutation leads the methyl binding domain 
(MBD) of MeCP2 to sample an alternative conformational space that impairs its ability to interact with 
DNA. These results have been experimentally confirmed in electrophoretic mobility shift assays 
comparing the ability of WT and Y120D MBD polypeptides to bind methylated and unmethylated DNA 
[15]. Interestingly, the conversion of Y120 into F did not affect the DNA binding properties of the MBD 
of MeCP2. Similarly, here we demonstrate that WT and Y120F MeCP2 show a similar ability to recruit 
TBL1 on heterochromatin, while the mutant Y120D protein has lost such ability. All in all, these data 
suggest that harboring a tyrosine residue is not crucial for MeCP2 functions, while its conversion into 
aspartate, or possibly in a negatively charged residue, is a key detrimental step. 
In line with the clinical features of the Y120D RTT patient [16], the Y120D mutation in mice leads to a 
harsh condition that is only slightly less severe compared to the total absence of the protein. Indeed, a 
progressive deterioration of the animal condition, in particular of the neurological aspects (mainly related 
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to mobility, learning and memory functions), becomes overt after a short period of apparently normal 
development and eventually these mice die prematurely.  
The molecular characterization of this novel mouse model revealed several features that are highly 
relevant for research on MeCP2 and Rett syndrome. 
First, although the Y120D mutation is supposed to impair Mecp2 binding to DNA, the molecular 
phenotypes associated with the mutant protein (reduced affinity for chromatin, inability to accumulate 
on heterochromatic foci and bulk increase in chromatin accessibility) become evident mainly in mature 
neurons when protein levels are also halved. We recently suggested that Mecp2 changes its functions 
during brain maturation [19]. In particular, in developing brains and neurons the protein is not tightly 
bound to chromatin and largely co-sediments with nucleosome-free DNA. Possibly due to diverse post-
translational modifications (i.e. phosphorylation) during brain maturation, MeCP2 attains a tight 
association with nucleosomal DNA and chromatin, probably also acquiring structural functions, as 
already proposed [7]. Thus, it is conceivable that the molecular consequences of harboring the missense 
mutation Y120D become more severe in adult brain, when mutant MeCP2 fails in acquiring its expected 
structural functions. Nevertheless, the impaired DNA binding is expected to somehow affect the 
transcriptional properties of MeCP2 also in early development, therefore leading to functional alterations. 
Accordingly, we demonstrate that early responsiveness to stimuli of Mecp2Y120D cultured neurons is 
impaired. 
Theoretically, all MeCP2 mutants characterized by a reduced DNA binding should share the herein 
described molecular phenotypes. Indeed, an effect on protein stability of the RTT mutations T158M and 
R133C has already been proved. Interestingly, destabilization of mutant Mecp2 appeared to positively 
correlate with the reduction in DNA binding [12, 14]. However, in apparent discordance with our results, 
the Mecp2T158A mouse shows a significant decrement in proteins levels already at perinatal age that 
worsens with time [14]. Similarly, Lamonica et al. found that the protein expression levels of the mutant 
Mecp2T158M are reduced of almost 20% at P0 and further decreased at P7 and P15; no further decrement 
was observed beyond this developmental stage [39]. 
So far, it is not clear why mutations in T158 cause an earlier effect on protein levels compared to Y120D. 
We propose that unbound Mecp2 is more rapidly degraded in mature neurons than in immature cells, 
which are physiologically characterized by a more dynamic association of the protein with chromatin. In 
addition, as already suggested [40], Mecp2 degradation might be affected by its post-translational 
20 
 
modifications and it is conceivable that Mecp2-Y120D is diversely modified with respect to T158A/M. 
Accordingly, we demonstrate that the Mecp2Y120D/y mature brain exhibits a significant increase in S164 
phosphorylation. However, since the Y120D mutation somehow mimics the effect of Y120 
phosphorylation that occurs more frequently in the immature brain [15], it is also possible that the Y120D 
missense mutation has a minor impact on the developing brain compared to the T158M/A mutations. 
Thus, although in the future we will investigate whether a different combination of post-translational 
modifications occurs on Mecp2-Y120D, currently we cannot exclude that the mutated Mecp2 T158M 
protein is more impaired in its DNA binding properties and therefore more effectively degraded in the 
brain since early development. 
Several studies suggest that one of the most relevant activities of MeCP2 in brain is the recruitment of 
corepressors on methylated DNA, leading to an inaccessible and transcriptionally silent chromatin 
structure [4, 30]. Considering that in mature neurons the protein is so abundant to bind the majority of 
methylated cytosines, its effects are likely exerted on the whole genome (Fig.6,  “WT”).  We  demonstrate  
that in cells expressing the Y120D mutant, the molecular partners of Mecp2, such as NCoR and ATRX, 
are not properly recruited on heterochromatin. As a result, in the Mecp2Y120D mature brain, chromatin is 
globally more accessible compared to WT brain, in line with the increased levels of S5 phosphorylated 
RNA Polymerase II and the concomitant increase in 5-hmC levels, suggesting an increased 
transcriptional activity (Fig.6,  “Y120D”).  Unexpectedly,  the  consequences  of  the  total  absence  of  Mecp2  
are quite different and do not appear to cause the hypothesized general decrease in chromatin compaction 
[19]. Indeed, we found that mature Mecp2-null brains do not have a more accessible chromatin structure, 
but instead exhibit a reduced MNase accessibility particularly on heterochromatic DNA. Furthermore, 
Mecp2-null brain nuclei manifest reduced levels of actively transcribing RNA polymerase II and 5-hmC. 
Skene et al. proposed that in mature neurons MeCP2 acts as a chromatin architectural factor whose 
absence is compensated by the up-regulation of histone H1 [7] (Fig.6,  “null”).  Our  data   confirm   the  
existence of compensatory mechanism(s) but also suggest that these compensations lead to a more 
packed chromatin structure. In possible accordance, several studies profiling transcription in Mecp2-null 
brains unexpectedly reported the down-regulation of the majority of differentially expressed genes [4, 




These data highlight that although mutations of Mecp2 might produce largely concordant behavioral 
phenotypes in mice, they can diversely compromise Mecp2 functions therefore leading to discordant 
compensatory mechanisms and/or alterations in chromatin structure. Although future studies will reveal 
the extent to which these diversities affect transcriptional profiles, our results indicate that effective 
therapeutic strategies might differ depending on the specific genetic mutation. For example, by 
increasing the expression of Mecp2-T158M, Lamonica et al. demonstrated that the reduced levels of the 
mutant protein are contributing to RTT pathogenesis [39]. Considering that mutations in the MBD might 
generally destabilize MeCP2, the authors proposed that therapies able to stabilize or increase the 
expression of mutant MeCP2 might have the potential to benefit most RTT patients carrying mutation in 
the MBD of MeCP2. However, we propose that the stabilization therapy might not be so beneficial in 
patients carrying a mutation that impairs the fundamental interaction of MeCP2 with NCoR [42], as it 
occurs with the MeCP2-Y120D alteration.  
The molecular mechanism by which Y120D mutation impairs the NCoR binding is possibly due to a 
general change in the motions/dynamical profile of the MBD, while the T158M mutation mainly affects 
the structure of the domain [14]. Indeed, we demonstrated that, despite Y120 is not in direct contact with 
DNA, its mutation in D leads to an altered mobility of the domain and to a defective communication 
between the domain residues [15]. This impaired communication and profile of mobility/flexibility can 
be propagated to the entire protein, thus affecting the interaction with NCoR/SMRT. This long-range 
communication between the two protein domains could explain why the T158M and Y120D mutations 
have a different effect on the protein function although they are both located in the MBD. 
To conclude, we suggest that only a thorough comprehension of the molecular alterations that affect 
Mecp2-null and knockin animal lines mimicking human pathogenic mutations will truly highlight the 
molecular consequences of MeCP2 deficiency and the possible existence of convergent molecular 
defects. Emphasis should be given on comparing Mecp2-null models with animals carrying human 
mutations that affect or not affect MeCP2 binding to DNA together (or not) with an influence on its 
ability to associate with its interactors. These comparisons will help clarifying whether treatment of 
MECP2-related diseases should consider a personalized approach in which patients are stratified in 
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FIGURE LEGENDS 
Fig.1. The novel Mecp2Y120D mouse line manifests severe RTT-like symptoms and short lifespan (a) 
Schematic representation of the Mecp2 locus targeting strategy exploited for the insertion of the Y120 
mutation. See also Fig.S1. (b) DNA sequencing electropherogram showing the presence in the generated 
animals of the single point mutation T>G – highlighted – that leads to the substitution of Y120 with an 
aspartic acid (D). (c) qPCR assay shows no difference in the Mecp2 mRNA levels of P30 C57BL/6J 
Mecp2Y120D/y (n=4) cortices, compared to Mecp2+/y (n=3). Data are represented relative to Mecp2+/y, as 
mean  ±  s.e.m.  Significance  is  calculated  by  Student’s  t  test.  (d) Mecp2Y120D/y mice in C57BL/6J and CD1 
background (n=8 and 11, respectively) show reduced lifespan compared to Mecp2+/y littermates (n=6 and 
9, respectively). Significance is calculated by Log-rank (Mantel-Cox) test (*P<0.05, ****P<0.0001). (e) 
Plots showing the progression of the phenotypic score (cumulated for general condition, mobility, hind 
limb clasping and -only for CD1- tremor values) of C57BL/6J and CD1 mutated males (animals 
evaluated: n=6 C57BL/6J and 10 CD1 Mecp2Y120D/y vs 7 C57BL/6J and 9 CD1 Mecp2+/y). Analyses 
ended when there were less than 3 animals per group. Data are represented as mean ± s.e.m. Significance 
is calculated by two-way ANOVA. Plots of single variable are showed in Fig.S2. (f) Plot showing the 
progression of the phenotypic score (cumulated for general condition, mobility, hind limb clasping and 
tremor values) of CD1 heterozygous females (animals evaluated: n=7 Mecp2Y120D/+ vs 8 Mecp2+/+). 
Analyses ended when there were less than 3 animals per group. Data are represented as mean ± s.e.m. 
Significance is calculated by two-way ANOVA. Plots of single variable are showed in Fig.S2. (g) Plots 
showing the progression of total body weight of C57BL/6J and CD1 mutated males in comparison with 
control littermates (animals evaluated: C57BL/6J n=6 Mecp2Y120D/y vs 7 Mecp2+/y; CD1 pups n=19 
Mecp2Y120D/y vs n=17 Mecp2+/y; CD1 adult n=10 Mecp2Y120D/y vs 9 Mecp2+/y). Analyses ended when there 
were less than 3 animals per group. Data are represented as mean ± s.e.m. Significance is calculated by 
multiple t test (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001). (h) Plot showing the progression of 
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total body weight of CD1 heterozygous females in comparison with control littermates (animals 
evaluated: pups n=18 Mecp2Y120D/+ vs n=14 Mecp2+/+; adult n=7 Mecp2Y120D/+ vs 8 Mecp2+/+). Analyses 
ended when there were less than 3 animals per group. Data are represented as mean ± s.e.m. Significance 
is calculated by multiple t test (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001). (i) Brain weight was 
measured in juvenile (P18, n=4 Mecp2Y120D/y vs 7 Mecp2+/y), young adult (P40, n=18 Mecp2Y120D/y vs 14 
Mecp2+/y) and adult (CD1 P>130 n=4 per genotype, C57BL/6J P>80 n=5 per genotype) mice. Measures 
of brain weights are expressed as mean ± s.e.m, Significance is calculated by Student’s  t  test  (*P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001).  
Fig.2. CD1 Mecp2Y120D mice are impaired in motor performance and short-term memory. See also 
Table S1. (a) Rotarod test showing the persistence on the rotating bar of P30 Mecp2Y120D/y (n=24) 
compared to Mecp2+/y (n=14) littermate mice. P30 Mecp2Y120D/y mice show altered motor coordination 
(acceleration phase, day 1) and increased muscle fatigue (constant speed, day 2). (b, c) Gait analyses 
with CatWalk XT software show small strides in the knockin mice. Analyses were performed on P30 
Mecp2Y120D/y (n=24) and Mecp2+/y (n=14), and P60 Mecp2Y120D/y (n=12) and Mecp2+/y (n=16) littermate 
mice. Stride length of right front (RF), right hind (RH), left front (LF) and left hind (LH) paws were 
measured in (b) and the base length of front and hind paws in (c). (d) The strength of front paw muscles 
was measured through grip strength test on P30 Mecp2Y120D/y (n=24) and Mecp2+/y (n=14), and P60 
Mecp2Y120D/y (n=12) and Mecp2+/y (n=17) littermate mice. The panel shows maximum values. (e) 
Working memory defects in P30 Mecp2Y120D/y (n=12) and Mecp2+/y (n=17) littermate mice assessed with 
the spontaneous alternation test. Mecp2Y120D/y mice show decreased percentage of correct alternation with 
the same number of entries compared to WT animals. (f) Impaired tone (cue; conditioned stimulus CS) 
memory in P30 Mecp2Y120D/y (n=13) and P60 Mecp2Y120D/y (n=22) mice compared to their Mecp2+/y 
littermates (P30, n=15; P60, n=9) during the auditory fear conditioning test. Graphs represent the 
percentage of freezing during the 5 tones (CS) of training phase (left panels), during the context test 24 
hours after training (middle panels) and during the cue test (right panels). Data are presented as means ± 
s.e.m. For statistical analyses see Materials and Methods (*P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001). (g) Calcium imaging experiments in cultured E15.5 cortical neurons reveal precocious 
and persistent functional alterations in Mecp2Y120D/y neurons. Representative traces and relative 
quantification of KCl-induced calcium transients in WT and Mecp2Y120D/y cells are depicted. Whereas 
resting calcium levels are indistinguishable in the two groups during neuronal development 
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(Mecp2+/y=0.487±0.005 vs Mecp2Y120D/y=0.480±0.006; t test Mann-Whitney Rank Sum Test: P=0.373), 
KCl administration leads to reduced calcium influxes in both DIV4 (g’: Mecp2+/y=0.39±0.013 vs 
Mecp2Y120D/y=0.29±0.009; t test Mann Whitney Rank Sum Test: ***P<0.001; number of analyzed cells: 
Mecp2+/y=184 vs Mecp2Y120D/y=147) and DIV13 Mecp2Y120D/y cultures (g’’: Mecp2+/y=0.404 ±0.010 vs 
Mecp2Y120D/y=0.368±0.009; t test Mann-Whitney Rank Sum Test: **P=0.005; number of analyzed cells: 
Mecp2+/y=155 vs Mecp2Y120D/y=189; resting calcium levels Mecp2+/y=0.50±0.004 vs 
Mecp2Y120D/y=0.52±0.006; t test Mann-Whitney Rank Sum Test P=0.096). (h) NMDA delivery induces 
smaller calcium transients in immature DIV4 mutated neurons (h’: DIV4; Mecp2+/y=0.313±0.011 vs 
Mecp2Y120D/y=0.267±0.011; t test: *P=0.027) and comparable calcium responses in mature cells (h’’: 
DIV13; Mecp2+/y=0.409±0.012 vs Mecp2Y120D/y=0.408±0.012; t test: p=0.612). Number of analyzed 
cells: Mecp2+/y DIV4=150, DIV13=184; Mecp2Y120D/y DIV4=150, DIV13=189). 
Fig.3. The Y120D mutation affects Mecp2 abundance and its chromatin binding properties in 
mature neurons. (a) Representative images and western blot quantification of Mecp2 protein levels 
assessed on E16 brains and P6, P18, P40 cortices of Mecp2Y120D/y and Mecp2+/y CD1  males  (n≥  5  per  
genotype at each time point). Data are represented relative to Mecp2+/y, as mean ± s.e.m. Significance is 
calculated  by  Student’s  t  test  (***P<0.001, ****P<0.0001). (b) Representative images and western blot 
quantification of Mecp2 protein levels of Mecp2Y120D/y and Mecp2+/y E15.5 cortical neurons at different 
DIVs  (n≥  10  per  genotype  at  each  time  point).  Data  are  represented  relative  to  Mecp2+/y, as mean ± s.e.m. 
Significance is calculated by Student’s  t  test  (*P<0.5). (c) Western blot quantification showing altered 
P-rpS6 and P-S164 levels in cortices of P40 Mecp2Y120D/y CD1 mice (n=7 Mecp2Y120D/y vs 5 Mecp2+/y). 
Data are represented relative to Mecp2+/y, as mean ± s.e.m. Significance is calculated by  Student’s  t  test  
(*P<0.5, ***P<0.001). (d) Representative images of Mecp2+/y and Mecp2Y120D/y cultured neurons 
established from E17.5 cortices and immunostained at different DIV for DAPI (left panels) and Mecp2 
(middle panels). Mecp2Y120D/y nuclei show diffused staining that does not overlap with DAPI-
heterochromatic foci (white arrows). Images were taken at 100X magnification. (e, f) Upper panels: 
representative western blots showing salt extraction of WT or mutant Mecp2 with increasing 
concentrations of NaCl from P6 and P40 mouse CD1 brains. H1 was included as control of the salt 
extraction procedure. Lower panels: quantification of the fraction of WT and Y120D Mecp2 extracted 
with different concentration of NaCl. Data are represented as mean ± s.e.m. Significance is calculated by 
two-way ANOVA followed by Bonferroni post-hoc test. (*P<0.05, **P<0.01, ***P<0.001, 
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****P<0.0001). (g) Nuclei were purified from Mecp2+/y and Mecp2Y120D/y P40 brains and resuspended in 
buffers containing 200 mM, 300 mM, 400 mM or 1M NaCl. Extracted Mecp2 was tested by western blot 
(n=2). 
Fig.4. The Y120D mutation affects the capacity of Mecp2 to recruit its corepressors on chromatin. 
(a) Representative images of Mecp2-null mouse embryonic fibroblasts (MEF) transfected with eGFP-
MeCP2 derivatives to study the recruitment of the TBL1-mCherry construct on heterochromatic foci [5]. 
TBL1 is efficiently recruited on the DAPI-positive heterochromatic foci in 58% of cells expressing 
eGFP-MeCP2-WT (n=60), in 45% of cells expressing eGFP-MeCP2-Y120F (n=60) and only in 19% of 
the eGFP-MeCP2-Y120D ones (n=62). In no cell transfected with eGFP alone TBL1-mCherry (n=20) 
was recruited on heterochromatic foci. Images were taken at 40X magnification. The contrast and 
brightness parameters for each channel were adjusted to obtain a clear representation of the results. (b) 
Representative images showing the heterochromatic localization of ATRX in WT brains, in contrast to 
the diffuse staining of ATRX observable in Y120D sections (n=3 animals per genotype; 60X 
magnification). 
Fig.5. Mecp2Y120D brain exhibits different chromatin features compared to Mecp2-null and WT 
brains. (a) Representative images of chromatin accessibility assessed by digesting with MNase P40 
Mecp2+/y and Mecp2Y120D/y and Mecp2+/y and Mecp2-/y brain nuclei. Purified digested DNA was loaded 
on a 2% agarose gel. For a similar analysis performed at P6, see Fig.S4. (b) Graphs showing the fraction 
of mononucleosomal DNA on total DNA at each time point (5, 10 and 20 min) of Mecp2+/y and 
Mecp2Y120D/y (b’, n=3) and Mecp2+/y and Mecp2-/y (b’’, n=3) samples. Data are expressed as mean ± s.e.m. 
No statistical significance was reached by two-way ANOVA followed by Bonferroni post-hoc test.  (c) 
DAPI staining of MNase-treated nuclei isolated from P40 Mecp2+/y and Mecp2Y120D/y and Mecp2+/y and 
Mecp2-/y littermate cortices. Purified nuclei were digested with MNase for 5 and 10 min before staining. 
Undigested nuclei (UT) were DAPI stained for comparison (n= 60 to 110 nuclei for each experimental 
group). Heterochromatic area stained by DAPI was measured in Mecp2Y120D/y nuclei and Mecp2-null 
nuclei (c’), while total nuclear intensity is displayed in c’’. Data are expressed as percentage of the 
untreated WT and are represented as mean ± s.e.m. Significance was calculated by two-way ANOVA 
followed by Bonferroni post-hoc test (**P<0.01, ***P<0.001, ****P< 0.0001). (d) Mecp2Y120D/y nuclei 
show higher Pol II-S5P transcriptional signal compared to Mecp2-/y. Representative images of RNA Pol 
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II S5P staining of Mecp2Y120D/y and Mecp2-/y cortical nuclei at P40 and their respective controls are 
displayed. Graphs represent the intensity of Pol II-S5P signal of d’) Mecp2+/y and Mecp2Y120D/y nuclei 
and d’’) Mecp2+/y and Mecp2-/y nuclei (n=100 nuclei for each experimental group). Data are expressed 
as percentage of WT and are  represented  as  mean  ±  s.e.m.  Significance  is  calculated  by  Student’s  t test 
(****P<0.0001). (e) Graphs represent the percentage of 5-hmC in brain cortices of P40 Mecp2+/y, 
Mecp2Y120D/y and Mecp2-/y mice (n=5 for Mecp2Y120D/y and respective controls; n=5 for Mecp2-/y and 
respective controls). Data are expressed as percentage of WT and are represented as mean ± s.e.m. 
Significance  is  calculated  by  Student’s  t  test  (*P<0.5).  
Fig.6. A model for the different chromatin structure in Mecp2-null and Mecp2Y120D/y brains. Several 
studies have proposed that in brain MeCP2 is globally bound to chromatin where it recruits different 
remodeling chromatin complexes, therefore leading to a specialized chromatin structure  (“WT”  panel).  
Loss of MeCP2 protein would lead to compensatory mechanisms that double histone H1 levels [7] and 
lead  to  a  more  condensed  and  transcriptionally  inert  chromatin  structure  (“null”  panel).  In  the  Y120D  
knockin brain, the labile interaction between MeCP2 and DNA and the concomitant delocalization of its 
corepressors such as NCoR and ATRX lead to a more accessible and transcriptionally active chromatin 
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